Spots Global Cancer Trial Database for modified t cells
Every month we try and update this database with for modified t cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | NCT01860937 | Relapsed B-Cell... | leukapheresis o... cyclophosphamid... modified T cell... | - 26 Years | Memorial Sloan Kettering Cancer Center | |
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
CD30 CAR for CD30+ NSGCT | NCT05634785 | Germ Cell Tumor Nonseminomatous... | ATLCAR.CD30 Cel... Cyclophosphamid Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | NCT01416974 | Leukemia | cyclophosphamid... modified T cell... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | NCT01416974 | Leukemia | cyclophosphamid... modified T cell... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center |